Physician
Pathology
Dr. James W. Denham, MD
|
|
Give Review
James Denham practices Pathology. He went to Louisiana State University School of Medicine in New Orleans. James W. Denham is a published doctor and has 101 publications published. The lastest was: 'Long-term results of accelerated radiation treatment for advanced head and neck cancer.' He is registered with Medicare and accepts Medicare payments.
Publications
- Radiation induced bowel injury: a neglected problem.
- Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats.
- A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Su...
- Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cance...
- Direct dose to water dosimetry for pretreatment IMRT verification using a modified EPID.
- Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer.
- Another form of subgroup to beware.
- Targeted therapies: An important piece of the localized prostate cancer puzzle?
- A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis o...
- Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: the jury must remain out.
- Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?
- Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
- Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
- Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
- Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the pr...
- Breast edema in patients undergoing breast-conserving treatment for breast cancer: assessment via high frequency ultrasound.
- Radiation damage to the gastrointestinal tract: mechanisms, diagnosis, and management.
- Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer.
- Normal tissue effects: reporting and analysis.
- Bowel injury: current and evolving management strategies.
- Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology...
- Radiation-induced changes in cellularity and proliferation in human oral mucosa.
- Defining pelvic-radiation disease for the survivorship era.
- It''s time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trials.
- Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point.
- "Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship.
- A methodology for the analysis of PSA response signatures.
- Does the planning dose-volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans.
- MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning.
- A magnetic resonance imaging-based workflow for planning radiation therapy for prostate cancer.
- Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
- MRC RT01: an important trial.
- Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised c...
- Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial.
- PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?
- Thrombin generation as a predictor of radiotherapy induced skin erythema.
- Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
- ''When measurements mean action'' decision models for portal image review to eliminate systematic set-up errors.
- Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
- Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controll...
- The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
- Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
- The radiotherapeutic injury--a complex ''wound''.
- Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood.
- Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
- Survival benefit confirmed for prostate cancers diagnosed by PSA testing.
- A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.
- Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial.
- All delays before radiotherapy risk progression of Merkel cell carcinoma.
- Decision-making models in the analysis of portal films: a clinical pilot study.
- Acute toxicity and cost analysis of a phase III randomized trial of accelerated and conventional radiotherapy for squamous carcinoma of the head and neck: a Trans-Tasm...
- A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis.
- Is there more than one late radiation proctitis syndrome?
- Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?
- Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Insti...
- Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)
- Mucosal regeneration during radiotherapy. Trans Tasman Radiation Oncology Group (TROG).
- Underprediction of human skin erythema at low doses per fraction by the linear quadratic model.
- Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer.
- Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom.
- Long-term results of accelerated radiation treatment for advanced head and neck cancer.
- A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
- Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy.
- How should we introduce high-dose chemotherapeutic strategies into the adjuvant management of high-risk breast cancer in Australasia?
- Response of human hair cortical cells to fractionated radiotherapy.
- Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.
- A study of high frequency ultrasound to assess cutaneous oedema in conservatively managed breast.
- Comparison of prostate set-up accuracy and margins with off-line bony anatomy corrections and online implanted fiducial-based corrections.
- Assessment of a daily online implanted fiducial marker-guided prostate radiotherapy process.
- Low dose rate teletherapy: updated tumour response.
- Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
- Factors influencing the degree of erythematous skin reactions in humans.
- Acute reaction parameters for human oropharyngeal mucosa.
- Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison.
- Concurrent chemoradiation for oesophageal cancer: factors influencing myelotoxicity.
- Fatigue during breast radiotherapy and its relationship to biological factors.
- Pilot study of high-frequency ultrasound to assess cutaneous oedema in the conservatively managed breast.
- Treatment-time-dependence models of early and delayed radiation injury in rat small intestine.
- Extinction of the weakest.
- Verification of surface dose on patients undergoing low to medium energy X-ray therapy.
- Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans?
- TLD extrapolation for skin dose determination in vivo.
- Is it time for a new formalism to categorize normal tissue radiation injury?
- Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
- Clinical use of carbon-loaded thermoluminescent dosimeters for skin dose determination.
- Altered amino acid homeostasis and the development of fatigue by breast cancer radiotherapy patients: A pilot study.
- Comprehensive Australasian multicentre dosimetric intercomparison: issues, logistics and recommendations.
- A combined modality approach to the management of oesophageal cancer.
- Prostate cancer screening in Australasia.
- How do we bring an acceptable level of radiotherapy services to a dispersed population?
- Regarding actuarial late effect analyses: Bentzen et al., IJROBP 32:1531-1534; 1995 and Caplan et al., IJROBP 32:1547; 1995.
- Combined modality therapy for carcinoma of the oesophagus: current status and future directions.
- Verification of the dose distribution for 192Ir mould treatments using radiochromic film and LiF:Mg,Cu,P TLDs.
- A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group S...
- Prostate cancer: low alpha/beta the only consideration? In regard to Fowler, Chappell, and Ritter: the prospects for new treatments for prostate cancer.
- Evaluation of rectal shielding in a Henschke system applicator.
- LiF:Mg,Cu,P ''pin worms'': miniature detectors for brachytherapy dosimetry.
- A timely reminder.
- Erythema: goodbye LQ!
- A pilot study of dermofilm in acute radiation-induced desquamative skin reactions.
Schools
Louisiana State Univ School Of Medicine In New Orleans
Univ Of Tenn
Baptist Memorial Hospital
Doctors Specialties
- Pathology
Accepted Insurances
- Aetna
- Blue Cross Blue Shield
- Bluegrass Family Health
- Cigna
- Commercial Insurance Company
- GEHA
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medical Mutual of Ohio
- Medicare MCR
- Mutual of Omaha
- POMCO Group
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
East Tennessee State University -
University of Tennessee -
Louisiana State University School of Medicine in New Orleans
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1902088644 |
| Last Name Of The Provider | DENHAM |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Jack T. Bechtel Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin Pierce, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan L. Kulbacki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Hudgens, MD |
|
|
Dr. Theresa S. Emory, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul J. Sides Jr., MD
This Doctor is OpenDoctor Recommended.
|